Monday 13 December 2010 11:48 am More From Our Partners Brave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgSupermodel Anne Vyalitsyna claims income drop, pushes for child supportnypost.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgMark Eaton, former NBA All-Star, dead at 64nypost.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgKiller drone ‘hunted down a human target’ without being told tonypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.com whatsapp whatsapp Show Comments ▼ THE European Central Bank’s sovereign bond buying programme picked up last week – but is still far below the levels forecast by some analysts as needed to allay fears over eurozone debt.The ECB said it bought €2.67bn (£2.23bn) worth of bonds in the week to December 3, up from €1.97bn the previous week and taking the programme’s overall total to €72bn.The spend was the biggest weekly amount since late June, but remains just a fraction of the €16.5bn of bonds bought in the first week of the programme in May.The low level cast doubt over speculation that the bank had moved the programme up a gear.ECB President Jean-Claude Trichet earlier this month stressed that the programme was still in effect, leading some observers to expect a larger tally this week.“We didn’t have any promise from the ECB to do a particular level of purchases, but the view in the markets had been that the ECB had scaled up its purchases to a greater extent, ” RBS economist Nick Matthews said.“There may be some disappointment.”The figures may not give the full picture, however. The ECB adds the caveat that the total may be higher than reported as purchases take 2-3 days to finalise.The ECB can buy government and corporate bonds under the purchase programme but it has given no further details, such as how much it could spend or how long it intends to buy for.The purchases are the central bank’s contribution to a €750bn EU/IMF rescue package hastily brought in at the height of the debt crisis in May.Most analysts believe it is concentrating its purchases exclusively on euro zone debt trouble spots Ireland, Greece and Portugal.The ECB publishes the amount of bonds it has purchased on a weekly basis every Monday.As usual it will take one-week deposits from banks on Tuesday to offset the inflationary impact of pumping money into the financial system via its bond purchases. ECB bond buying still lower than anticipated Share alison.lock Tags: NULL
If you’re looking for a reliable, market-beating income, which stocks should you buy for 2020?In this article I want to take a look at three FTSE 100 firms whose recent performance makes me think they could be among the best dividend stocks in the UK market.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…For me, a good dividend stock is one that has a track record of growth, is covered by earnings, and provides a yield that’s above the FTSE 100 average of 4.3%.Here are three companies I think tick all the right boxes.A 6% yield I’d buyLegal & General Group (LSE: LGEN) has a big presence in the pension and insurance sectors. During the first half of 2019, the group reported annuity sales of £7bn and a 15% increase in assets under management, which rose to £1,135bn.L&G’s scale is definitely a key attraction for me. But I also think this company enjoys very strong management. Chief executive Nigel Wilson has adapted his strategy to changing pension markets and made the company very profitable.For shareholders, a key attraction is the group’s strong cash generation. The dividend has risen from 9.3p in 2013 to a forecast payout of 17.5p per share for 2019. Despite this growth, the payout is still covered 1.8 times by earnings.Analysts expect the dividend to rise by 6.5% to 18.7p per share in 2020. This gives LGEN shares a forecast dividend yield of 6.3% for 2020.I believe Legal & General is one of the best dividend stocks in the FTSE 100.Big holes, big payoutsMining giant Rio Tinto (LSE: RIO) isn’t a household name, at least not in the UK. But the firm’s Australian iron ore mines are among the biggest and most profitable in the world.Low costs and strong demand have kept profits high in recent years. But chief executive J-S Jacques has kept spending under tight control. He’s used much of the spare cash generated by the group’s mines to cut debt and pay generous dividends.The outlook for 2020 is actually a little more subdued than for 2019. Analysts expect profits to fall this year, with a corresponding reduction in the size of the dividend. However, it’s still early in the year. The outlook may yet improve.As things are today, Rio Tinto offers a forecast yield of 6% for 2020. Although an industrial slowdown in China could hit profits, I think investing in Rio could be a great way to diversify your portfolio.The best in its class?Motor insurer Admiral Group (LSE: ADM) is a well-known name. But what you may not realise is that this company is far more profitable than most of its rivals. The main reason for this is Admiral’s approach to risk.Essentially, the firm pays other insurance companies to take some of the claims risk in return for a fixed fee. Because of the way insurers are regulated, this means that Admiral doesn’t need to hold as much cash in reserve for possible claims.The end result is that the company is extremely profitable and generates a lot of surplus cash. Most of this is returned to shareholders through a combination of ordinary and special dividends.Admiral shares aren’t the cheapest in this sector. But they offer a forecast dividend yield of 5.4% and benefit from one of the best track records in the market. I’d keep buying. Roland Head | Monday, 20th January, 2020 | More on: ADM LGEN RIO Our 6 ‘Best Buys Now’ Shares Image source: Getty Images. I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Admiral Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. See all posts by Roland Head “This Stock Could Be Like Buying Amazon in 1997” Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Simply click below to discover how you can take advantage of this. I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Enter Your Email Address Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Are these the best dividend stocks for 2020?
“COPY” “COPY” Year: photographs: Desmond Han, Goh Kim HuiPhotographs: Desmond Han, Goh Kim HuiSave this picture!© Desmond Han, Goh Kim HuiRecommended ProductsFiber Cements / CementsULMA Architectural SolutionsPaper Facade Panel in Leioa School RestorationFiber Cements / CementsApavisaTiles – Nanofusion 7.0Fiber Cements / CementsRieder GroupFacade Panels – concrete skinFiber Cements / CementsEQUITONEFiber Cement Facade Panel NaturaText description provided by the architects. The project set out to address a common occurrence in multi-storeyed residences: the dark lobby.Save this picture!© Desmond Han, Goh Kim HuiLobbies in commercial typologies, more often than not, are dark and claustrophobic to maximize saleable area in the building. In this, with its triangular plot and L-shaped plan, maximum saleable area is achieved by strategic placement of the lift core at the edge.Save this picture!© Desmond Han, Goh Kim HuiA central courtyard within providing an airy, bright space, a private tropical haven that can be shared by all.Save this picture!© Desmond Han, Goh Kim HuiSave this picture!SectionSave this picture!© Desmond Han, Goh Kim HuiProject gallerySee allShow lessSimple House / ScapelabSelected ProjectsShrimp / UID ArchitectsSelected ProjectsProject locationAddress:SingaporeLocation to be used only as a reference. It could indicate city/country but not exact address. Share ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/780003/killiney-road-ipli-architects Clipboard Killiney Road / ipli architectsSave this projectSaveKilliney Road / ipli architects 2013 ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/780003/killiney-road-ipli-architects Clipboard Singapore CopyAbout this officeipli architectsOfficeFollowProductsSteelConcreteBrick#TagsProjectsBuilt ProjectsSelected ProjectsMixed Use ArchitectureResidential ArchitectureHousingApartmentsCommercial ArchitectureSingaporePublished on January 08, 2016Cite: “Killiney Road / ipli architects” 07 Jan 2016. ArchDaily. Accessed 11 Jun 2021.
About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving. 70 total views, 1 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis JustGiving Awards 2012 winners announced Tagged with: Awards Digital Justgiving Howard Lake | 6 March 2012 | News Online fundraising site JustGiving has announced the winners of its annual awards for the best online fundraising by the individuals and charities that use the site. The winners received their awards at a ceremony at London’s Shoreditch Town Hall.The winnersMost Popular fundraiser – YogscastYoung Fundraiser of the Year – Lauren GanderMost Creative Fundraiser – Alison PowellEndurance Fundraiser of the Year – Dave HeeleyPayPal Fundraiser of the Year – Simon AdamsCharity of the year (people’s choice) – AspireMost Creative Charity of the Year – MencapBest New Charity – Rett Syndrome Research Trust UKCelebrity Fundraiser of the Year – Richard ParksVodafone mobile fundraiser of the year – STV Charitable TrustWorkplace fundraiser of the year – Barton WillmoreBest use of Technology – MerlinLifetime Achievement Award – Harry MoseleyIt looks like plenty of other charities are winners too in another sense. JustGiving is about to pass the £1 billion milestone of money raised for charity.The eventUK Fundraising was there to capture the highlights of the inspiring and often moving event.The awards get underway.Alison Powell wins Most Creative FundraiserVodafone Mobile Fundraiser of the YearRett Syndrome Research Trust UK wins Best New CharityBob Wilson accepts highly commended awardSimon Adams wins Fundraiser of the YearJoanna Lumley announces Aspire as charity of the yearHarry Moseley receives Lifetime Achievement AwardYoung fundraiser of the yearwww.justgiving.com Advertisement AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis
The big-business media — TV, radio, the press — is overflowing with good news on the economic front. But the question is whether or not the news is true and whether the media analysts are interpreting it correctly.Here is their news: The U.S. gross domestic product — which is the sum of all goods and services produced in the U.S. — is up 20 percent since 2008. (St. Louis Federal Reserve) The official unemployment rate is 3.9 percent, after reaching a high of 10.2 percent in October 2009, and the median household income is now $61,372. (Bureau of Labor Statistics)The tax cuts, which flew through Congress to President Trump’s desk in record time, mean more take-home pay in nearly everyone’s paycheck.Despite the media’s optimism and good cheer, workers and the poor face a harsher reality. Over 8 million people have no health insurance. Even for those who have insurance, co-pays and deductibles can push the cost of life-saving drugs like insulin out of reach.Housing is impossibly expensive in many cities. Using New York as an example, it takes a few million dollars to buy a two-bedroom apartment in Manhattan or you can rent such an apartment for $7,000 to $8,000 a month. Outside of Manhattan, market rents are less, but still unreachable for many workers who make less than the median wage.New York is at the upper end of housing costs in the United States, but elsewhere housing costs are also fueling the rise in homelessness and taking bigger and bigger chunks of workers’ incomes.Manhattan is the epicenter of U.S. capital, the physical home of Wall Street, filled with new construction, tourists and displays of vast wealth. Because the real estate firm Douglas Elliman was having trouble renting storefront property these days in Manhattan, it conducted a survey of vacancy rates. It found that 20 percent of Manhattan storefronts are currently vacant, up from 7 percent in 2016. (The Real Deal, Sept. 9)That vacancy rate is a bad sign for the economy.There are vacant stores on Fifth Avenue, one of the most exclusive shopping streets in the world, on posh 57th Street and on 14th Street, a mecca for working-class shoppers for decades. The alleged recovery from the 2008-09 crisis is neither consistent, nor coherent, despite the improvement in unemployment statistics.Unemployment rate: deception and accuracyThe current calculation of the unemployment rate involves dividing the number of jobless people who are looking for work by the total labor force — defined as all those people working or actively looking for work. In August that was 3.9 percent.If you factor in underemployed workers, those working less than full time not by choice, “discouraged” workers, those marginally attached — who would work but feel they can’t find a job — that adds about 12.3 million people to the unemployed total. This raises the rate of unemployed to 7.6 percent.Even this rate is incomplete because it doesn’t count the 2.2 million people locked up in jails, who are most certainly part of the working class. There have been a number of prison strikes from coast-to-coast since the beginning of August, which meant prisoners were asserting their status as workers by withholding their labor.For the last 30 years people of prime working age, 25 to 54, have been leaving the labor force in greater and greater numbers for a variety of reasons. To get a figure that better reflects economic reality, some economists have been urging the government to report a rate that is a simple ratio of “employed people aged 25-54 divided by the total population between ages 25-54.”That labor force participation rate is better now than it was in 2009. But it’s not a record you can boast about. It was around 67 percent in 2000. (St Louis Federal Reserve)The 3.9 percent official unemployment rate is not false news, but it doesn’t accurately reflect what is happening to jobs in the U.S. economy. All of these rates ignore the special problems that people of color, youth and elders, Native people, mothers who want or have to work, and anyone with less schooling and training have in finding and keeping jobs. The government and the media just want one number, especially if it makes the system look good.If those in office can claim that unemployment is low and the economy is good, it blames the individual jobless worker. It gives the government a pretext to avoid funding job training and investments in job creation.Rise in the GDP and incomesTo be more precise, the gross domestic product is the monetary measure of the market value of all the final goods and services produced in a period of time, generally a quarter (three months) or a year. The U.S. GDP grew by 20 percent from the first quarter of 2009 to the first quarter of 2018.The question is: What does this growth mean for workers?The growth of the GDP fueled a tremendous surge in business profits, which meant that returns to the wealthy who collected them also surged. But in 2016, net worth among white middle-income families was down 19 percent below 2007 levels (adjusted for inflation). Among Black families, net worth was down 40 percent; for Latinx families, it was down 46 percent.The major contribution to the net worth of Black and Latinx families is the investment they make in their homes. However, home prices still have not recovered. White families started out with higher levels of wealth, with a smaller proportion of it in their homes. (New York Times, Sept. 12)In August, the median wage for all workers — the wage where half of all workers’ wages are lower and half are higher — reached where it had been in 2007 (adjusted for inflation). This means that after a decade of “recovery,” wages are back where they had once been.An Economic Policy Institute Jan. 6, 2015 report on wage stagnation makes the point that “middle-class wages are stagnant — middle-wage workers’ hourly wage is up 6 percent since 1979, low-wage workers’ wages are down 5 percent, while those with very high wages saw a 41 percent increase.”Fox News and Trump supporters express surprise about the lack of popular enthusiasm for the state of the economy, which is booming for Wall Street, the banks and the super-rich. Yet for the vast majority of workers, the state of the economy is grim.FacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare this
Limerick Chamber chief executive Dee RyanPhoto: Oisin McHughLIMERICK people are being asked to spend locally this Christmas and support small businesses as the shopping season hits fever pitch.Amongst those making the call is Limerick Chamber chief executive Dee Ryan who said that Limerick shoppers could go long way to supporting the independent retailers of the city and county and in turn this would support jobs and businesses.Sign up for the weekly Limerick Post newsletter Sign Up The Irish Small Firms Association said that the strong economy and rising employment rates across the country will raise consumer spirits and enable greater spending power over this year’s busy Christmas shopping period.SFA director Sven Spollen-Behrens explained that “if each adult spent just €20 extra in small businesses this Christmas, this would amount to an injection of over €73 million for small Irish firms and would have a huge, positive impact on local jobs and the vibrancy of town and village centres.“Small business must take every opportunity to offer the widest possible range of goods at the most competitive prices if they are to attract as many Christmas shoppers as possible. Today’s shoppers are very value-conscious and there are great deals to be had in small businesses around the country.“Retail employs more people in Ireland than any other sector of the economy. Consumers should think about this when making their Christmas shopping decisions, as this time of year is make or break for many small retailers. We are calling on consumers to shop locally in small businesses and buy Irish products,” he said. Print WhatsApp WATCH: “Everyone is fighting so hard to get on” – Pat Ryan on competitive camogie squads TAGSbusinessChristmaslimerickLimerick City and CountyNews Twitter Limerick Ladies National Football League opener to be streamed live Advertisement Limerick’s National Camogie League double header to be streamed live Linkedin Billy Lee names strong Limerick side to take on Wicklow in crucial Division 3 clash RELATED ARTICLESMORE FROM AUTHOR Facebook Predictions on the future of learning discussed at Limerick Lifelong Learning Festival Email NewsBusinessChristmas shoppers urged to spend locallyBy Staff Reporter – December 9, 2018 1024 Previous articleMunster get the job done but big improvement neededNext articleThe Christmas tree and the Nutcracker Staff Reporterhttp://www.limerickpost.ie Donal Ryan names Limerick Ladies Football team for League opener
Print KILLER Tom Martens has settled a wrongful death action taken against him and will pay Jason Corbett’s children, Jack and Sarah, €160,000.The civil action taken by Mr Corbett’s estate after his brutal murder had been listed before the US courts but was settled this week without the admission of liability.Sign up for the weekly Limerick Post newsletter Sign Up Fellow killer, Molly, was not included in the wrongful death action and it is also understood that she will not benefit from the €530,000 insurance policy payout to the Limerick man’s estate, nor can she initiate any claim.A €17,500 trust fund payment to Jack and Sarah Corbett will also be made from an insurance company acting for Tom Martens and his wife Sharon.Limerick man and father of two Jason Corbett (39) was savagely beaten in his bed by father and daughter Tom and Molly Martens at his North Carolina home in August 2015.The pair were tried and convicted of second degree murder and sentenced to between 20 and 25 years in prison.This week, Jason’s sister and guardian to his two orphaned children, Tracey Corbett Lynch, told the Irish Independent that “we are relieved as a family to close this difficult chapter and try to move forward with our lives and focus on our children.The settlement comes after a four year battle with the Martens’ in both US civil and criminal courts.However, Molly, Jason’s second wife and her father have appealed their convictions and a US appeal court has heard the case and is considering its decision.Ms Corbett Lynch said that she hopes to travel to the US to retrieve Jason’s belongings but added that “what we want now is to continue to focus on ensuring those responsible for Jason’s murder remain in prison.” WhatsApp TAGSCourtCrimeJason CorbettNews Linkedin Facebook Brother of slain Jason Corbett writes to US President expressing “dismay” at DA’s plea bargain offer to killers Family of Jason Corbett “devastated” after receiving “bombshell” news his killers will get bail after being offered “manslaughter” plea deal Jason Corbett killers, Molly and Tom Martens may be freed on bail tomorrow as they consider manslaughter plea bargain deal Shannon Airport braced for a devastating blow Previous articleCarbery and Mathewson extend their Munster dealsNext articleLimerick man charged with nightclub murder of father of one appears in court Staff Reporterhttp://www.limerickpost.ie Email Twitter NewsCrime & CourtMartens settles Jason Corbett wrongful death caseBy Staff Reporter – March 26, 2019 3430 RELATED ARTICLESMORE FROM AUTHOR Advertisement Limerick on Covid watch list Local backlash over Aer Lingus threat
Pinterest Crime, conflict, chaos crushing Afghan hopes for tomorrow Facebook Local NewsWorld News Facebook WhatsApp Twitter TAGS Pinterest Twitter By Digital AIM Web Support – February 4, 2021 WhatsApp Previous articleGenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human PrimatesNext articleSt. John’s shuts down No. 3 Villanova in 70-59 upset Digital AIM Web Support
Previous articleGlobal 5G Tariff Report Bundle 2021 – Includes 5G Pricing for 40 Countries and 91+ Operators Across the Globe – ResearchAndMarkets.comNext articleAsia Pacific Healthcare Workwear Market Forecast to 2027: Growing Demand for Healthcare Workwear due to Coronavirus Outbreak – ResearchAndMarkets.com Digital AIM Web Support WhatsApp Pinterest ThermoDox for Hepatocellular Carcinoma (August 4, 2020)ThermoDox for Hepatocellular Carcinoma (July 13, 2020)Imfinzi for Hepatocellular Carcinoma (May 29, 2020)Multiple Drugs for Hepatocellular Carcinoma (May 29, 2020)Tecentriq for Hepatocellular Carcinoma (November 22, 2019)Tecentriq for Hepatocellular Carcinoma (October 21, 2019)Opdivo for Hepatocellular Carcinoma (September 27, 2019)Tecentriq for Hepatocellular Carcinoma (September 27, 2019)Opdivo for Hepatocellular Carcinoma (June 24, 2019)Keytruda for Hepatocellular Carcinoma (June 2, 2019)Namodenoson for Hepatocellular Carcinoma (March 26, 2019) KEY UPCOMING EVENTS KEY OPINION LEADER INSIGHTS UNMET NEEDS For more information about this report visit https://www.researchandmarkets.com/r/fwaf0s View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005543/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH ONCOLOGY SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/09/2021 04:55 AM/DISC: 02/09/2021 04:55 AM http://www.businesswire.com/news/home/20210209005543/en Global Hepatocellular Carcinoma (HCC) Market Analysis to 2038 – HCC Sales in the US, Japan, France, Germany, Italy, Spain, and UK to Rise to $2.5Bn by 2027 – ResearchAndMarkets.com By Digital AIM Web Support – February 9, 2021 WhatsApp Pinterest Facebook DUBLIN–(BUSINESS WIRE)–Feb 9, 2021– The “Hepatocellular carcinoma (HCC) Disease Coverage Forecast and Market Analysis to 2038” report has been added to ResearchAndMarkets.com’s offering. The publisher estimates that in 2018, there were 682,000 incident cases of hepatocellular carcinoma (HCC) worldwide in those aged 40 years and older, and forecasts that number to increase to 812,000 cases by 2027. The majority of HCC diagnoses (70.7%) worldwide are in males, ranging from 56.0% to 72.4% across regions. Nexavar has been firmly established as the standard of care in advanced HCC since gaining approval in the US in 2007. However, Nexavar is forecast to steadily lose market share after the introduction of generics in 2020 (US), 2021 (EU), and 2022 (Japan). Additionally, Nexavar will face strong competition from the combination of Tecentriq and Avastin, which was the first regimen to demonstrate both superior overall survival (OS) and progression-free survival (PFS) over Nexavar in the Phase III IMbrave150 study. The publisher forecasts HCC sales in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) to rise from $681m in 2018 to $2.5bn in 2027. Numerous PD-1/PD-L1 therapies are expected to be approved as monotherapies or as part of combination regimens for the first-line treatment of advanced HCC, and are expected to see significant uptake in this setting. Furthermore, the approval of expensive combination therapies in HCC will continue to drive market growth despite the generic erosion of key brands such as Nexavar. After demonstrating a PFS benefit and non-inferior OS to Nexavar in the Phase III REFLECT study, Lenvima became the second systemic therapy approved as a first-line treatment for HCC in 2018. However, Lenvima is also expected to face significant competition from both the combination of Tecentriq and Avastin and from other immunotherapy regimens in development for the first-line setting. The loss of revenue to these therapies could be mitigated by approval of a Lenvima and Keytruda combination, which is currently being tested in the Phase III LEAP-002 trial. Following positive results from the Phase III RESORCE trial, Stivarga was the first therapy to be approved for HCC patients previously treated with Nexavar, in 2017. However, Stivarga now faces strong competition for these previously treated patients from targeted therapies Cabometyx and Cyramza, and immune checkpoint inhibitor therapies Opdivo, Yervoy, and Keytruda. Although Cyramza failed to meet its primary endpoint in the Phase III REACH trial, the subsequent Phase III REACH-2 trial confirmed the drug’s efficacy in the subgroup of patients with high levels of alpha-fetoprotein (AFP), and supported a US approval for HCC patients who have been previously treated with Nexavar and have AFP levels ?400ng/mL. Cyramza faces competition from Cabometyx and Stivarga, which are also approved for patients who have progressed on Nexavar, and from immunotherapies. Cabometyx is approved in the US and EU for HCC patients who have progressed on Nexavar, where it faces competition from Stivarga, Cyramza, and the immunotherapies. Exelixis is also pursuing the combination of Cabometyx and Tecentriq for use in the first-line setting in the Phase III COSMIC-312 study, with topline results expected in the second half of 2020. Imfinzi with tremelimumab, a PD-L1 inhibitor + CTLA-4 inhibitor combination, is being investigated for the first-line treatment of advanced HCC in the Phase III HIMALAYA trial. AstraZeneca is also investigating Imfinzi for the treatment of patients with locoregional HCC in the Phase III EMERALD-1 study and for the adjuvant treatment of patients with HCC who are at high risk of recurrence after hepatic resection or ablation in the Phase III EMERALD-2 study. Approval in these settings would help to differentiate Imfinzi from other PD-1/PD-L1 inhibitors in HCC. In 2017, Opdivo became the first drug in the PD-1/PD-L1 inhibitor class approved in the US for the treatment of advanced HCC patients who have progressed on Nexavar. Additionally, the combination of Opdivo and Yervoy received an accelerated approval in March 2020 for the same treatment setting, becoming the first regimen containing a drug in the PD-1/PD-L1 inhibitor class combined with a CTLA-4 inhibitor approved for HCC in the US. However, Opdivo’s commercial potential beyond this setting is limited because the Phase III CheckMate 459 trial testing its use in the first-line setting failed to show a statistically significant OS benefit in comparison to Nexavar. Keytruda was approved shortly after Opdivo for patients who have progressed on Nexavar, in 2018. Both therapies were approved under accelerated pathways based on Phase II data. Although the confirmatory Phase III KEYNOTE-240 trial of Keytruda failed to meet its primary endpoint due to the statistical plan chosen for the study and the impact of post-study treatment on survival results, Keytruda remains an approved therapy for HCC. Following the failure of Opdivo’s CheckMate 459 trial, tislelizumab is the only PD-1/PD-L1 inhibitor being developed as a monotherapy for previously untreated HCC patients. Given the expected competition in the first-line setting, tislelizumab’s commercial potential will be determined by its cost-benefit ratio compared to the combination regimens, as well as its efficacy in patients who are unable to tolerate combination therapy. Key recent events include pivotal trial readouts, such as positive results for Tecentriq and Avastin in the Phase III IMbrave150 trial in the first-line setting and Opdivo’s failure to show an OS benefit over Nexavar as a first-line monotherapy in the Phase III CheckMate 459 trial, as well as key regulatory events, such as the US approval of Tecentriq in combination with Avastin and the complete response letter for the combination of Keytruda and Lenvima in the first-line treatment setting. Key upcoming catalysts for 2020 and early 2021 include the topline results from the Phase III HIMALAYA study of Imfinzi and tremelimumab, and topline results from the Phase III COSMIC-312 study of Cabometyx and Tecentriq. The overall likelihood of approval of a Phase I HCC asset is 8.3%, and the average probability a drug advances from Phase III is 43.5%. HCC drugs, on average, take 10.5 years from Phase I to approval, compared to 9.4 years in the overall oncology space. Key Topics Covered: OVERVIEW DISEASE BACKGROUND DefinitionRisk factorsSymptomsScreeningDiagnosis TREATMENT Referral patternsPatient segmentationVery early and early-stage HCC (Stages 0-A)Intermediate HCC (Stage B)Advanced-stage HCC (Stage C)Terminal-stage HCC (Stage D)Recurrence EPIDEMIOLOGY Incidence methodology MARKETED DRUGS PIPELINE DRUGS KEY REGULATORY EVENTS Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another ApprovalKeeping Track: A Good Week For Interstitial Lung Diseases; Opdivo+Yervoy Gains Liver Cancer Claim PROBABILITY OF SUCCESS CLINICAL TRIAL LANDSCAPE Sponsors by statusSponsors by phaseRecent events DRUG ASSESSMENT MODEL MARKET DYNAMICS FUTURE TRENDS Launches of PD-1/PD-L1 inhibitor combinations will drive growth in the HCC market over the forecast periodLabel expansions into earlier treatment settings could expand the number of HCC patients treated with systemic therapyPipeline drugs will face fierce competition in the first-line settingGeneric or biosimilar erosion of key brands will have minimal impact on growth CONSENSUS FORECASTS RECENT EVENTS AND ANALYST OPINION Facebook Twitter Local NewsBusiness Twitter TAGS
Community Enhancement Programme open for applications Homepage BannerNews Google+ News, Sport and Obituaries on Monday May 24th Twitter Google+ RELATED ARTICLESMORE FROM AUTHOR Facebook South Inishowen now has highest Covid incidence rate in Donegal Previous articleGardai seize quantity of fireworks in RameltonNext articleWithdrawn school sanitizer could eventually be used – Minister News Highland Pinterest By News Highland – October 30, 2020 Facebook WhatsApp Arranmore progress and potential flagged as population grows Loganair’s new Derry – Liverpool air service takes off from CODA Nine til Noon Show – Listen back to Monday’s Programme Important message for people attending LUH’s INR clinic Twitter Pinterest South Inishowen is now the local electoral area with the highest Covid-19 14-day incidence rate in Donegal. While most areas in the county have recorded a fall this week, the incidence rate in both Letterkenny and South Inishowen has increased.The latest figures cover the 14 days up to last Monday.South Inishowen now has an incidence rate of 603.6 per 100,000 – the highest in the county.But Letterkenny recorded the biggest jump countywide, going from 275.3 per 100,000 last week to 443.1 cases, according to the latest data.All other areas have recorded falls this week with Lifford Stranorlar seeing a big drop – its incidence rate now stands at 305.1 per 100,000 compared with 509.9 last week.North Inishowen decreased to 247.6 per 100,000 from 336 while Donegal’s incidence rate is currently at 264.2 cases per 100,000 compared with 320.9 in the previous data.Meanwhile Glenties has recorded an incidence rate of 112.9 per 100,000, a fall from 154.7 while Milford has also fallen to 94.4 cases per 100,000, compared with 116.2 last week. WhatsApp